Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors

The Netherlands Cancer Institute45 enrolled

Overview

This study aims to evaluate anatomical and functional changes during RT for patients receiving fractionated RT for brain tumors. Anatomical changes during RT will be registered and analyzed and if needed the radiotherapy plan will be modified for the individual patient. This means that the "to be irradiated volume" will be modified according to the shape changes of the tumor. The functional MRI sequences will be used to evaluate what parameters, and at which time point, are important for radiotherapy outcome.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Brain Tumor

Interventions

RadiotherapyRADIATION

standard radiotherapy treatment with 1-3 extra MRIs

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primary brain tumor (WHO IV, GBM); treated with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy. * Brain metastasis (from a solid extracranial tumor) eligible for treatment with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy. Also, postoperative patients with a macroscopic residual tumor lesion can be included (the diagnosis of residual diseases is defined by the treating neurosurgeon or on the MRI executed within 24 hours after the surgery, the diagnosis of residual macroscopic disease should always be confirmed during the neuro-oncology multidisciplinary meeting). Exclusion Criteria: * Patients receiving Whole Brain RT (WBRT) * Patient with a poor kidney function (GFR \< 30 mL/min; CKD 4 and 5; patients on dialysis and patients with acute kidney insufficiency) * None, doubtful or very small (\<5 mm in its largest dimension) contrast enhancing lesion * Patients with a contraindication for MRI

Locations (1)

Antoni van Leeuwenhoek

Amsterdam, North Holland, Netherlands

Outcomes

Primary Outcomes

MRI parameters in the target volume

functional MRI parameters (permeability, perfusion and diffusion) in the target volume before and during fractional radiotherapy treatment

Time frame: through study completion, an average of 3 years

anatomical variations in position, shape and size in the target volume

The difference is position shape and size in the target volume before and during fractional radiotherapy treatment. In case there is no macroscopic extension beyond the clinical target volume the new target volumes (gross target volume (GTV) and clinical target volume (CTV).) will also (but later) be delineated for analysis of volume changes, center of mass changes and distance measurements between the delineation on planning MRI versus repeated MRI.

Time frame: through study completion, an average of 3 years

Secondary Outcomes

the correlation between MRI parameters to the treatment outcome

to make a sample size calculation for a future study of imaging marker discovery.

Time frame: through study completion, an average of 3 years

the correlation between anatomical variations and the treatment outcome

to make a sample size calculation for a future study of imaging marker discovery.

Time frame: through study completion, an average of 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.